Novel Immuno-Oncology Pathways
Pioneering New Cancer Antigens & Antibodies

TSX-V: VXL
Orphan Drug Status
2017 Advancing to Phase-II
VAXILBIO.com
Strong Business History

10 years of successful research and development with substantial investment and large Phase-II next

- 1st Patent
  - Israel
- 1st PATENT

Israel Office of Chief Scientist
- First of $2M

First Published Medical Journal
- Vaxil 1st Article

2007 2008 2009 2010 2011 2012

Vaxil in Elsevier
- Vaxil gets major publication


1st US Patent
- For ODS tech

Orphan Drug
- FDA and EMA

Hadassah
- Significant Collaboration

Potential Accelerated

Israel INC.

- First Published Medical Journal
- Vaxil 1st Article
- Integration
- Founded by Weizmann PhDs

- Phase-I/II Results
- Renowned BJH

- TSX Listing
- $3M raised

- PD1 CTLA4
- Initial testing

- Combinations
- Up to 100pts

Phase-II Results
- New hires
- New lab

- 6 Granted Patents
- Plus 10 More Pending

- Potential for Major Phase-II in 2017

- $12-Million invested
- 10 years of achievements

- Successful Phase-I/II
- Orphan Drug Status
Right Product Right Market

Advantageous product in rapidly growing immunotherapy field

KEY ADVANTAGES

- Vaxil has the ability to select high profile cancer markers and target them in an altogether novel manner
- All products developed in-house with VaxHit platform, a proprietary algorithm
- Vaxil’s lead product, ImMucin™, has been awarded Orphan Drug Designation after a successful Phase-I
- Novel MOA with robust immunity in 100% of patients
- Better specificity as well as long term clinical benefit
- Acts as neo-antigen able to elicit robust response
- Ability to advance to much larger Phase-II with approximately 100 cancer patients

MONUMENTAL INDUSTRY

“A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history” REUTERs

“Researchers hail new cancer treatment: Unlocking the body’s immune system” CNN

“Killing cancer from the inside out” Bloomberg

“Harnessing the immune system to fight cancer, long considered a dream, is becoming a reality. Remarkable stories of tumors melting away” The New York Times

OFF THE SHELF PRODUCTS

Synthetically produced compound which can support long term maintenance therapy

ROBUST IP PORTFOLIO

<table>
<thead>
<tr>
<th>ImMucin™</th>
<th>GRANTED</th>
<th>GRANTED</th>
<th>GRANTED</th>
<th>GRANTED</th>
<th>GRANTED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody Platform</td>
<td>PENDING</td>
<td>PENDING</td>
<td>PENDING</td>
<td>–</td>
<td>PENDING</td>
</tr>
<tr>
<td>Anti Infectives</td>
<td>GRANTED</td>
<td>PENDING</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Top pharma companies recognize immuno-oncology as the future

- Vaxil™ Bio Ltd. is a cutting edge Israeli immuno-oncology proprietary platform technology VaxHit™ includes identification, isolation, and use of known cancer antigens as therapeutics
- VaxHit™ first generated therapy, ImMucin™ has been clinically validated for MUC1, a critical antigen over-expressed in 90% of cancers
- ImMucin has received FDA and EMA Orphan Drug Status for Myeloma
- Vaxil has a strong team, robust pipeline, solid IP with 6 patents and 10 additional pending
### Significant Cancer Types

Vaxil’s ability to apply its products to critical cancer indications

#### TOP 20 CANCER DRUGS BY 2020

<table>
<thead>
<tr>
<th>Drug</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kadcyla</td>
<td>Breast</td>
</tr>
<tr>
<td>Zytiga</td>
<td>Prostate</td>
</tr>
<tr>
<td>MPDL</td>
<td>Bladder</td>
</tr>
<tr>
<td>Gazyva</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>Xgeva</td>
<td>Myeloma</td>
</tr>
<tr>
<td>Abraxane</td>
<td>Breast</td>
</tr>
<tr>
<td>Yervoy</td>
<td>Melanoma</td>
</tr>
<tr>
<td>Tasigna</td>
<td>Leukemia</td>
</tr>
<tr>
<td>Alimta</td>
<td>Lung</td>
</tr>
<tr>
<td>Pomalyst</td>
<td>Myeloma</td>
</tr>
<tr>
<td>Keytruda</td>
<td>Lung</td>
</tr>
<tr>
<td>Herceptin</td>
<td>Breast</td>
</tr>
<tr>
<td>Perjeta</td>
<td>Breast</td>
</tr>
<tr>
<td>Ibrance</td>
<td>Breast</td>
</tr>
<tr>
<td>Rituxan</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>Xtandi</td>
<td>Prostate</td>
</tr>
<tr>
<td>Opdivo</td>
<td>Lung</td>
</tr>
<tr>
<td>Avastin</td>
<td>Bowel</td>
</tr>
<tr>
<td>Imbruvica</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>Revlimid</td>
<td>Myeloma</td>
</tr>
</tbody>
</table>

- Highest earning drug is a treatment for orphan disease Myeloma
- MUC1 found in 19/20 or 95% of the cancers treated by top-20 drugs
- 12/20 or 60% of the most important drugs are for Myeloma, Leukemia, Lymphoma, and Breast cancer, all next-in-line for Vaxil testing
**Need for Vaxil’s Therapies**

While rapidly growing, immunotherapy options currently possess real drawbacks.

**CHECKPOINT INHIBITORS**
- Checkpoint Inhibitors are only applicable in tumors which express the “checkpoint” proteins in high levels.
- Therefore not applicable to all cancer types.
- Tend to unleash “general immunity” which can cause moderate to severe side effects.

**CAR-T CELLS**
- CAR-T is also associated with moderate to severe side effects.
- Most results have to date been demonstrated on CD19 present in only certain cancer types.
- Requires considerable resources and must be individually administered.

**Conclusion:** Current immunotherapy options have limitations and challenges.

**Enter:** Vaxil pipeline, high safety profile, cancer specificity, and universal applicability.
Deep Pipeline

Technologies derived from proprietary VaxHit™ platform algorithm and include Orphan Drug Designated Immucin™

**Proprietary Platform**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHASE-0</td>
<td>Immucin™ - Targeting MUC1 in novel manner, Targeting other critical antigens</td>
</tr>
<tr>
<td>PHASE-I</td>
<td>Immucin™ - Ability to launch large Phase-II</td>
</tr>
<tr>
<td>PHASE-II</td>
<td>SPmAb™ - 1st Ever SP Antibodies, More specific to antigens</td>
</tr>
<tr>
<td>PHASE-III</td>
<td>MTbuVax™ - Superior Immunity, Seeking Partner</td>
</tr>
</tbody>
</table>

**Antigen Specific Neoantigens**

Immucin™ is a neoantigen acting immunotherapy MUC1

**Antibody Platform**

Antibody platform predicated on SP-specific mAbs target earliest stages of cancer. Potential to act as companion diagnostic with Immucin and as standalone therapeutic

**Infection Vaccines**

Isolated five 19 to 40mer signal peptide domain vaccine candidates derived M. tuberculosis antigens. Both in patient samples and in mice demonstrated immunogenic properties of the three top mixtures in inducing a strong and specific cellular response following a short regimen of active vaccination
VAXIL IMMUNOTHERAPY PLATFORM

VaxHit™

VAXIL IS THE ONLY IMMUNOTHERAPY COMPANY WORLDWIDE WORKING ON SIGNAL-PEPTIDE DOMAINS OF CANCER ANTIGENS AS THERAPIES

SAFE + STABLE
All products derived from VaxHit are chemically stable and synthetic, and do not require additional sophisticated adjuvants

CANCER EVASION
To the best of our knowledge, Vaxil’s products can potentially overcome cancer’s evasion mechanisms such as TAP deficiency

1 SIGNAL-PEPTIDE IMMUNO-ONCOLOGY
Vaxil is the pre-eminent immuno-oncology company with a specialized platform for developing SP immunotherapies

UNIVERSAL
VaxHit derived products such as Immucin are universal in the sense that they target multiple HLA repertoires
Proprietary Platform

Vaxil’s algorithm enables isolation, identification and subsequent use of antigen portions as therapeutics

1) Select Antigen
   - Antigen mining including selection of top priority cancer targets worthy of isolating

2) Vaxil Platform
   - Vaxil platform algorithm identifies and isolates best domains in signal peptide of selected antigen

3) Vaxil Platform
   - leading to validation of immune responses in human samples and other pre-clinical settings

ANTIGEN TARGET MINING

Identification of prime cancer targets compatible with Vaxil’s algorithm technology

VAXIL ALGORITHM

Identification, Isolation, Production of Signal Peptide Domains within Targeted Antigens

IMMUNE VALIDATION

Peripheral Blood Lymphocytes & Monocytes

T-Cells & Dendritic Cells

Syngeneic and HLA Transgenic mice
Key Vaxil Advantages

All Vaxil products developed through the VaxHit™ Platform possess the same unique advantages

The ability to target high-profile cancer antigens in an altogether novel manner

<table>
<thead>
<tr>
<th>ANTIGEN SELECTION</th>
<th>IMMUNE ACTIVATION</th>
<th>AVOID CANCER EVASION</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGNAL PEPTIDE HIGHLY EXPRESSED ON TUMOR CELLS, NOT NAÏVE CELLS</td>
<td>ALL DATA TO DATE SUGGESTS VAXIL ABILITY TO IMPACT CELLULAR AND HUMORAL IMMUNITY</td>
<td>BYPASS INTRACELLULAR CANCER MECHANISM WHICH AVOIDS IMMUNE</td>
</tr>
<tr>
<td>HIGHLY EXPRESSED ON METASTASIS AND CANCER STEM CELLS</td>
<td>UNIVERSAL RESPONSE VS SINGLE HLA RESTRICTED</td>
<td>MHC Ag PRESENTATION DOWN REGULATION ON TUMOR CELLS</td>
</tr>
<tr>
<td>NEO-ANTIGEN ACTING TRIGGERS FULL-SCALE IMMUNE RESPONSE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Significant Target

Ability to target high-profile cancer antigens in altogether novel and proprietary avenue

Vaxil strategically selected MUC1 as its initial target antigen utilizing VaxHit™ platform and the result has become the ImMucin™ immunotherapy

The Prioritization of Cancer Antigens
A National Cancer Institute Pilot Project

“The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on predefined and preweighted objective criteria”

- Therapeutic Function
- Immunogenicity
- Oncogenicity
- Expression Level
- Stem Cell Expression
- Number of Patients

<table>
<thead>
<tr>
<th>CANCER</th>
<th>10 year Survival</th>
<th>MUC1 Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple Myeloma</td>
<td>13%</td>
<td>YES</td>
</tr>
<tr>
<td>Leukemia</td>
<td>32%</td>
<td>YES</td>
</tr>
<tr>
<td>Pancreas</td>
<td>3%</td>
<td>YES</td>
</tr>
<tr>
<td>Liver</td>
<td>6%</td>
<td>YES</td>
</tr>
<tr>
<td>Lung</td>
<td>11%</td>
<td>YES</td>
</tr>
<tr>
<td>Stomach</td>
<td>19%</td>
<td>YES</td>
</tr>
<tr>
<td>Ovary</td>
<td>49%</td>
<td>YES</td>
</tr>
<tr>
<td>Colon</td>
<td>54%</td>
<td>YES</td>
</tr>
<tr>
<td>Kidney</td>
<td>54%</td>
<td>YES</td>
</tr>
<tr>
<td>Rectum</td>
<td>55%</td>
<td>YES</td>
</tr>
<tr>
<td>Larynx</td>
<td>57%</td>
<td>YES</td>
</tr>
<tr>
<td>Cervix</td>
<td>64%</td>
<td>YES</td>
</tr>
<tr>
<td>Breast</td>
<td>78%</td>
<td>YES</td>
</tr>
<tr>
<td>Hodgkin's</td>
<td>80%</td>
<td>YES</td>
</tr>
<tr>
<td>Prostate</td>
<td>95%</td>
<td>YES</td>
</tr>
<tr>
<td>Thyroid</td>
<td>96%</td>
<td>YES</td>
</tr>
<tr>
<td>Esophagus</td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>29%</td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>44%</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin's</td>
<td>46%</td>
<td></td>
</tr>
<tr>
<td>Urinary</td>
<td>76%</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>94%</td>
<td></td>
</tr>
</tbody>
</table>
VaxHit™ Platform

1. Inputs
   - UNMET MEDICAL NEED
   - KNOWN TUMOR ANTIGENS
   - BIOCLINICAL KNOWLEDGE

2. VaxHit™ Iterative process
   - SIGNAL PEPTIDE SCORE
   - IMMUNE RESTRICTION SCORE
   - FINAL ANTIGENIC POTENTIAL

3. Output
   - ANTIGEN PRODUCTION
   - IN-VITRO VALIDATION

Ability to target high-profile cancer antigens in altogether novel and proprietary avenue

VaxHit™ Iterative Process

NUMBER OF THERAPEUTIC CANDIDATES

MUC1
HER2
TB
Successful Phase-I/II

- N=15 Multiple Myeloma, demonstrated highly tolerable with high safety profile
- Robust, diversified immune response in 100% patients
- Stable Disease in majority of patients with long term clinical benefit to some
- Both B-Cells and T-Cells across major histocompatibility complex-barrier
- Secretion of key cytokines IFN-gamma and IL-2
- British Journal of Haematology 2014 published results in article entitled
  “Phase-I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine in multiple myeloma patients”

**OVERALL SURVIVAL**

**PROGRESSION FREE SURVIVAL**
# Vaxil Advantage

Advantageous technology demonstrating key benefits vs competition in wide range of factors

<table>
<thead>
<tr>
<th>BIOTECH:</th>
<th>Transgene</th>
<th>Prima Biotech</th>
<th>Oncothyreon</th>
<th>VAXIL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRODUCT</strong></td>
<td>TG-4010</td>
<td>CVac</td>
<td>Tecemotide</td>
<td>ImMucin™</td>
</tr>
<tr>
<td>Cancer Type Currently Tested</td>
<td>LUNG</td>
<td>OVARIAN</td>
<td>LUNG</td>
<td>MYELOMA</td>
</tr>
<tr>
<td>Antigen Specificity</td>
<td>NO</td>
<td>NO</td>
<td>Partially</td>
<td>YES</td>
</tr>
<tr>
<td>Antigen Expressed on Tumor Cells</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Negative affects of sMUC1</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Risk of Exhausted T-cell Immunity</td>
<td>PROBABLY</td>
<td>PROBABLY</td>
<td>PROBABLY</td>
<td>LESS LIKELY</td>
</tr>
<tr>
<td>Induce CD4+ &amp; CD8+ &amp; Antibodies</td>
<td>NO</td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Universal Vaccine (applicable to all immune repertoires)</td>
<td>YES</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Ability to cope with TAP-mutations (ability to cope with tumor resistance)</td>
<td>UNKNOWN</td>
<td>UNKNOWN</td>
<td>UNKNOWN</td>
<td>YES</td>
</tr>
<tr>
<td>Scalable (maintenance treatment)</td>
<td>YES</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td><strong>Valuation:</strong></td>
<td>Mkt Cap 160,000,000</td>
<td>NASDAQ 60,000,000</td>
<td>NASDAQ 100,000,000</td>
<td>TSX ~10,000,000</td>
</tr>
</tbody>
</table>
ImMucin comprises the entire antigen signal peptide (SP) domain of MUC1

ImMucin has a novel mechanism-of-action with **improved specificity**

Acts as **neo-antigen** able to elicit robust response against tumors

**Allogeneic:** ImMucin doesn't require patients’ selection based on their immune (MHC) repertoire

Dual MOA with TAP-dependent and independent T-cell activation, suppress tumor evade mechanisms

**Synthetically produced compound** which can support long term maintenance therapy

### Standalone Therapy and Attractive Combination Potential

| CANCER TYPE                  | PERCENTAGE POSITIVE FOR PD-L1 EXPRESSION* | PRESENCE OF TUMOR-INfiltrATING IMMUNE CELLS?  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>40%-100%</td>
<td><img src="image" alt="7,8" /></td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>35%-95%</td>
<td><img src="image" alt="9" /></td>
</tr>
<tr>
<td>Nasopharyngeal</td>
<td>68%-100%</td>
<td><img src="image" alt="10" /></td>
</tr>
<tr>
<td>Glioblastoma/mixed glioma</td>
<td>100%</td>
<td><img src="image" alt="11" /></td>
</tr>
<tr>
<td>Colon adenocarcinoma</td>
<td>53%</td>
<td><img src="image" alt="12" /></td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>45%-93%</td>
<td><img src="image" alt="13" /></td>
</tr>
<tr>
<td>Urothelial/bladder</td>
<td>28%-100%</td>
<td><img src="image" alt="14" /></td>
</tr>
<tr>
<td><strong>Multiple myeloma</strong></td>
<td><strong>93%</strong></td>
<td><img src="image" alt="15" /></td>
</tr>
<tr>
<td>Ovarian</td>
<td>33%-80%</td>
<td><img src="image" alt="16" /></td>
</tr>
<tr>
<td>Gastric carcinoma</td>
<td>42%</td>
<td><img src="image" alt="17" /></td>
</tr>
<tr>
<td>Esophageal</td>
<td>42%</td>
<td><img src="image" alt="18" /></td>
</tr>
<tr>
<td>Pancreatic</td>
<td>39%</td>
<td><img src="image" alt="19" /></td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>15%-24%</td>
<td><img src="image" alt="20" /></td>
</tr>
<tr>
<td>Breast</td>
<td>31%-34%</td>
<td><img src="image" alt="19" /></td>
</tr>
<tr>
<td>Lymphomas</td>
<td>17%-94%‡</td>
<td><img src="image" alt="21" /></td>
</tr>
<tr>
<td>Leukemias</td>
<td>11%-42%</td>
<td>-</td>
</tr>
</tbody>
</table>
VAXIL ANTIBODY PLATFORM SPmAb™

VAXIL HAS DEVELOPED THE FIRST-EVER SP-SPECIFIC ANTIBODIES

The importance of SP-Specific mAbs:

- Target novel antigen on cancer cells
- Avoids masking by soluble forms in circulation
- Show direct and indirect anti-tumor activity
- Can be used for screening of responding patient population
- Can potentially be used for anti-tumor therapy modalities

1st EVER

Vaxil is developing the 1st ever Signal Peptide Specific Antibodies

10%

Myeloma, Leukemia, and Lymphoma expected to account for 10.2% of all new 2016 cancer cases in the US

Source: Leukemia & Lymphoma Society
Highly Unique Antibody Platform

**FIRST EVER SP-SPECIFIC MABS - CRITICALLY IMPORTANT TARGET**

- MUC1-SP comprises promiscuous B-cell epitopes for inducing antibody response
- Non MHC-associated cell surface presence that can generate novel antibodies
- MUC1-SP mAbs recognize MUC1 SP on the BM of >80% of MM patients but not naïve individual
- Demonstrate specific binding to multiple MUC-1 expressing tumors
- Mediate functional specific anti-tumor cellular response
- Shown to induce anti-tumor response in a mouse cancer model
- Clinically relevant response seen in MM patients after ImMucin™ vaccination

**TUMOR PROGRESSION**

![Graph showing tumor progression over time for PBS, SPmAb-2.1, and SPmAb-6](image)
First-Ever **SP-Specific mAbs**, known as **SPmAb™**

- **VaxHit™** derived antibody known as **SPmAb™** platform possesses novelty & specificity.
- **SP-Specific mAbs** can be produced to directly attack the specific portion of antigens most associated with cancerous cells.
- These antibodies are expected to be specific enough to target tumor cells at earliest stages.
- Antibodies to MUC1 alpha subunit (TRA) will lead to less specific immune response due to antibodies-soluble antigen complexes.
- Addresses challenge of isolating novel antibodies against MUC1 cancer antigen.

**Normal Cell**

Certain antibodies target full antigens

**Cancer Cell**

SP-Specific antibodies seem to recognize cancer
If Vaxil is targeting cancer antigens found in 90% of all cancers, why start with blood cancers?

- Critical cancers in many cases considered incurable such as in the case of Myeloma
- Ability to effectively prove concept in traceable blood cancers with blood samples tracking results instead of arduous tumor biopsies
- Vaxil mission is prove concept on its core focus of haematological cancers while demonstrating ability to target cancer markers found in 90% of all cancers

Approx. every 3 minutes, 1 person in US is diagnosed with a blood cancer

Myeloma, Leukemia, and Lymphoma expected to account for 10.2% of all new 2016 cancer cases in the US

Source: Leukemia & Lymphoma Society
Myeloma – Leukemia – Lymphoma

Blood (haematological) cancers: Ideal starting point for Vaxil

- Up until 10 years ago, no cancer tests were able to detect minimal residual disease, whether a patient in remission is left with a small # of cancer cells

- Current biological tests allow for testing, meaning prediction of those likely for relapse after treatment

- Such patients need the option for a high-safety-profile and strong immunogenicity product

RESIDUAL CANCER (MRD) – CRITICAL INDICATOR
Myeloma – Leukemia – Lymphoma

- Sophisticated investors and big-pharma recognize the importance of immunotherapy and look to small-pharma for innovation
- Vaxil is the only company worldwide working on immunotherapy approaches through its specialty signal peptide algorithm platform
- Importantly, Vaxil has demonstrated its ability to develop therapies targeting high-profile antigens like MUC1 an otherwise elusive target

Blood (haematological) cancers: Ideal starting point for Vaxil

![Pie chart showing new cases by cancer type: Myeloma 18%, Lymphoma 47%, Leukemia 35%]

DEALS FOR PHASE-I/II IMMUNOTHERAPIES

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>CANCER</th>
<th>EQUITY INVESTMENT</th>
<th>UP-FRONT PAYMENT</th>
<th>POTENTIAL PAYMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase-I/II</td>
<td>Myeloma</td>
<td>$60-Million</td>
<td>$92-Million</td>
<td>$818-Million</td>
</tr>
<tr>
<td>Middle of initial trial for anti-CD38 Antibody</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase-I/II</td>
<td>Leukemia</td>
<td>$80-Million</td>
<td>$55-Million</td>
<td>$1.1-Billion</td>
</tr>
<tr>
<td>Partial results Phase-I/II anti-CD38 Antibody</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase-I/II</td>
<td>Lymphoma</td>
<td>n/a</td>
<td>$150-Million</td>
<td>$2.4-Billion</td>
</tr>
<tr>
<td>Deal for Phase-I trials Lymphoma / Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KEY TAKEAWAYS

- DEALS FOR PRODUCTS AT SIMILAR STAGE AS VAXIL
- RELEVANT INDICATIONS TO VAXIL
- TREND OF EQUITY INVESTMENT IN ADDITION TO LICENSING
VAXIL INFECTIOUS DISEASE PLATFORM

MTBuVax™ and Family of Vaccines

- MTBuVax generated from VaxHit
- Derived from strains of 5 known & novel tuberculosis targets
- Multi-antigenic, multi-epitope vaccine meaning broader applicability to patients
- Uniquely, utilized VaxHit™ technology for production of SP-Specific epitope targeting
- Already manifested superior immunity in over 200 blood samples vs current vaccines

“Today’s already large **700,000** deaths every year would become an extremely disturbing **10-Million** every year, more people than currently die from cancer”

Cancer

8.2-Million

2014

Super Bugs

10-Million

2050

FINANCIAL POST

Sat. Dec. 3, 2016 — The Guardian

SUPER BUGS: THEY’RE A HEALTH AND ECONOMIC CRISIS AND THERES NO CURE IN SIGHT

“Decades of antibiotic overuse have led to an increase in infections from bacteria that have developed a resistance to them, rendering the drugs that have conquered pneumonia, rheumatic fever and **tuberculosis powerless.**”
Clinical and Vaccine Immunology

Characterization of novel multi-antigenic vaccine candidates with pan-HLA coverage against Mycobacterium tuberculosis

“Low protection by the BCG vaccine and existence of drug-resistant strains require better anti-Mycobacterium tuberculosis vaccines with a broad, long-lasting, antigen-specific response. Using bioinformatics tools, we identified five 19- to 40-mer signal peptide domain vaccine candidates derived from M. tuberculosis antigens. Vaxil demonstrated both in patient samples and in mice results stressing the immunogenic properties of the three top mixtures in inducing a strong and specific cellular response following a short regimen of active vaccination.”
Vaxil recently announced a collaboration with one of Israel’s leading hospitals

- Vaxil and Hadassah, one of Israel’s most established hospitals in the heart of the country, recently announced a collaboration to jointly analyze Immucin utilizing Hadassah patient sampled

- Hadassah has expressed its eagerness to work with Vaxil and assist advancement in any way possible

RECENTLY ANNOUNCED VAXIL-HADASSAH COLLABORATION TO EXPLORE FURTHER PROJECTS


“I am a strong believer in Vaxil’s immunotherapy platform. I have spent years following Immucin’s progress, and have been fortunate to witness the promising potential both in cancer patients and in the lab.”

—Dr. Professor Michael Shapira
Hadassah Hospital
Dr. Saeid Babaei – Chairman
- Significant pharma experience
- Chairman, BriaCell Oncology
- Exit to NASDAQ listed Northern
- PhD, MBA, University of Toronto

Mr. Gadi Levin – CEO
- CPA with specialization in biotech
- Years of experience with Top-10 accounting firms and hedge funds
- Chartered Accountant

Mr. Isaac Maresky – Exec. Director
- Former investment banker with experience at Sunel, Standard, RBC
- Serial entrepreneur and youngest to IPO company on TSX Venture

Dr. Limor Chen – VP Operations
- Senior Researcher, TEVA
- Head of BD, Israeli listed NASDAQ
- PhD Weizmann, Dr. Ruth Arnon lab, developer of Teva’s Copaxone

Dr. Riva Kovjazin – Sr. R&D
- Immunology expert, Rostov Institute
- 10 years within Vaxil R&D
- Project Leader Clinical Immunology
- Medical Doctor

Dr. Benjamin Chen – Director
- Cancer Research Fellow, Stanford
- CEO ImaginAb immuno-oncology
- Senior R&D Systemix, acquired by Novartis, and Sentinel sold to Roche

Team includes 4 PhD scientists and medical doctors educated at top institutions in USA, Israel, Canada
**Financial Position**

**VAXIL REVAMPE**

Current market capitalization below book value

Robust immunotherapy pipeline advanced into the clinic at fraction price of earlier stage peers

Company has recently undergone restructuring, debt extinguished, financing, revamped R&D

**CAPITAL STRUCTURE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity Raised</td>
<td>$10.5 Million</td>
</tr>
<tr>
<td>Grants Obtained</td>
<td>$1.5 Million</td>
</tr>
<tr>
<td>Total Invested</td>
<td>$12 million</td>
</tr>
<tr>
<td>Shares Out</td>
<td>46.86 Million</td>
</tr>
<tr>
<td>Current Share Price</td>
<td>$0.14</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$6 Million</td>
</tr>
<tr>
<td>Cash on Hand</td>
<td>$1.5 Million</td>
</tr>
<tr>
<td>Debt</td>
<td>nil</td>
</tr>
<tr>
<td>Enterprise Value</td>
<td>$5.0 Million</td>
</tr>
</tbody>
</table>

**MILESTONES AHEAD**

- Vaxil has spent over a decade developing its proprietary immunotherapy pipeline
- Variety of near-mid-term milestones ahead
- Although to date the Company has not raised more than $12-Million, a major Phase-II with ~100 patients could serve to catalyze expansion and growth

**MARKET PRICE**

TSX-V: Vaxil Bio Ltd. Ticker: **VXL**
Share Price Nov 7th 2016: $0.12 CAD
Market Capitalization: $6-Million CAD

*3-Month Chart Source: Bloomberg*
Immunotherapy market is growing with immense potential including significant interest from global pharma.

- **Vaxil is the only company worldwide working on the use of SP domains as immunotherapy candidates and 1st ever SP-specific mAbs**
- Vaxil’s platform technology offers significant advantages over other solutions with many potential applications.
- ImMucin™, Vaxil’s lead Orphan Designated product under development, is well positioned with attractive and novel results vs. competing anti-MUC1 products.
- MTBuVax is a unique Tuberculosis vaccine also derived through VaxHit seeking partnership options as Vaxil focuses on oncology.
- Vaxil’s IP portfolio is strong and is fully owned by the company without any royalties.

**Conclusion**

Vaxil – Novel Immunotherapy Platform
All Vaxil articles are freely downloadable at www.VaxilBio.com

**VAXIL ARTICLES – MEDICAL JOURNALS**

**AMERICAN SOCIETY FOR MICROBIOLOGY**

CHARACTERIZATION OF NOVEL MULTITARGETED VACCINE CANDIDATES WITH PAN-HLA COVERAGE AGAINST MYCOBACTERIUM TUBERCULOSIS...

**ELSEVIER**

IMMUCIN™ A NOVEL THERAPEUTIC VACCINE WITH PROMISCUOUS MHC BINDING FOR THE TREATMENT OF MUC1 EXPRESSING TUMORS...

**bjh**

PHASE I/II STUDY EXPLORING IMMUCIN™ A PAN-MAJOR HISTOCOMPATIBILITY COMPLEX, ANTI-MUC1 SIGNAL PEPTIDE VACCINE, IN MULTIPLE MYELOMA PATIENTS...

**DISCLAIMER**

**DISCLAIMER – FORWARD LOOKING STATEMENTS:** This presentation does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire securities of Vaxil Bio Ltd. (the “Company”) in any jurisdiction, or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. The information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. None of the Company or any of its affiliates, advisors or representatives will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Information is in some places based upon approximations and rough estimates and include changing variables, and should not be relied upon. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. By accepting this document, participants agree to maintain absolute confidentiality regarding the information disclosed.
Vaxil Israel – R&D
Dr. Limor Chen, VP
Limor.Chen@VaxilBio.com

Vaxil maintains its lab in the Weizmann Science Park, adjacent to the renowned institution
13 Einstein Street
Ness Ziona, 7414001, Israel

Vaxil Canada – Corporate
Mr. Isaac Maresky, ED
Isaac.Maresky@VaxilBio.com

Vaxil Canada is conveniently located on Yonge Street just south of Sheppard subway station
4576 Yonge Street, Suite 604
Toronto, Ontario, M2N6N4, Canada